Francisco Javier Díaz de Teran Velasco

Randomized Controlled Trial of Lasmiditan Over Four Migraine Attacks: Interventional randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of eptinezumab for the preventive treatment of migraine in patients with a dual diagnosis of migraine and Medication Overuse Headache

A Multicenter Randomized, Double-Blind, Parallel-Group Study Evaluating the Long Term Safety, Tolerability, and Efficacy of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Migraine

ALDA03.CLIN-011: Parallel, double-blind, randomized, placebo-controlled Phase 3 trial to evaluate the efficacy and safety of ALDA03 administered Intravenously in patients with chronic migraine

TRIUMPH Study: preventive Treatment of migraine: outcomes for Patients in real-world Healthcare systems

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Episodic Migraine in Pediatric Patients 6 to 17 Years of Age

A 12-month prospective, randomized, interventional global, multi-center, active-controlled study comparing sustained benefit of two treatment paradigms (erenumab vs oral prophylactic) in adult episodic migraine patients

Phase 4 randomized, double-blind placebo controlled study to evaluate the efficacy and safety of Rimegepant in episodic migraine prevention with multiple dosing regimen

OnabotulinumtoxinA in high frequency episodic migraine

Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy and Safety of 2 Dose Regimens of Subcutaneous Administration of TEV-48125 versus Placebo for the Preventive Treatment of Chronic Migraine

Phase 2 multicenter, double-blind run-in phase followed by a 12-week, prospective, parallel-group, double-blind, randomized withdrawal placebo-controlled study, with a 52 week open label extension, to evaluate the efficacy and safety of daily 15 to 3.5 mg basimgurant in patients with pain associated with trigeminal neuralgia with suboptimal response to their current anti-pain therapy

Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy and Safety of 2 Dose Regimens of Subcutaneous Administration of TEV-48125 versus Placebo for the Preventive Treatment of Episodic Migraine

SIA phase 2, double-blind, randomized, placebo-controlled study to investigate possible drug-drug interactions between Clobazam and Cannabidiol (CWVP42003-P)